Scarce Enterprise MicuRx Pharmaceuticals Successfully Listed on STAR Market


HONG KONG, August 9, 2022 – (ACN Newswire) — On August 5, 2022, Legend Capital holding company MicuRx Pharmaceuticals, a rare super antibiotic company, successfully listed on the STAR Market. MicuRx Pharmaceuticals this time issued 130,000,000 shares, representing 19.84% of the total share capital after issuance. The total amount of funds raised is expected to be around RMB 960 million at an issue price of 8.16 yuan per share.


MicuRx Pharmaceuticals is an innovative pharmaceutical company focused on novel therapies for infectious diseases. With independent global intellectual property and competitiveness, MicuRx Pharmaceuticals is committed to the discovery, development and commercialization of innovative medicines for unmet medical needs. MicuRx Pharmaceuticals’ main products include Contezolid, MRX-4 and MRX-8. Since the company’s inception, MicuRx Pharmaceuticals has adhered to the principle of “Better Therapy Through Superior Medicine”, focusing on the growing problem of bacterial resistance around the world. With the core competitiveness of clinical problem solving and differentiated innovation, MicuRx Pharmaceuticals aims to provide more effective and safer treatment options for patients suffering from the most common and severe drug-resistant bacterial infections. MicuRx Pharmaceuticals has an international R&D team and has established R&D centers in China and the United States. The company’s R&D team has a wealth of experience in the development and management of innovative drugs internationally, and has led or participated in the development of a number of new marketed anti-infective drugs.

Legend Capital invested in MicuRx Pharmaceuticals in 2020 and has long supported the development of the company. “Congratulations to MicuRx Pharmaceuticals. This successful listing represents recognition of MicuRx Pharmaceuticals’ innovative R&D in the area of ​​multi-drug resistant bacterial infections and its globally competitive innovative drug. Legend Capital and the MicuRx team have established a deep friendship , and Legend Capital is honored to participate in the MicuRx venture led by Dr. Zhengyu YUAN, the founder of MicuRx Pharmaceuticals. Dr. YUAN is a very tenacious and spiritual entrepreneur who dares to take risks, filling the Chinese market gap in the rare field of drug-resistant bacterial multi-infection.With the consolidation of the forefront and position of the company, Dr. YUAN has not only built an international team and an innovative global company, but also brought positive contributions to the development of human health. Says Legend Capital.

Legend Capital has long paid particular attention to investing in significant themes in the field of life sciences. In addition to MicuRx Pharmaceutical, Legend Capital has also invested in many other outstanding companies, many of which were A- and H-share listed, such as Pharmaron (300759.SZ) (03759.HK), Kingmed Diagnostics (603882.SH) , Wuxi Apptec (603259.SH) (02359.HK), WuXi Biologics (02269.HK), Recbio (02179.HK), Innovent Biologics (01801.HK), Berry Genomics (000710.SZ), Harbor BioMed (02142. HK), New Horizon Health (06606.HK) and Chemclin Diagnostics (688468.SH).

About Legend Capital

Founded in 2001, Legend Capital is a leading venture capital and private equity investor focused on start-up and growth opportunities in China, with offices in Beijing, Shanghai, Shenzhen, Hong Kong and Seoul, in Korea.

It currently manages USD and RMB funds of over $10 billion in commitments and has invested in approximately 600 companies, spanning the technology, healthcare, consumer, business services and technology sectors. smart manufacturing. Rooted in China, Legend Capital has participated in the rise of many world-renowned companies through strong investment coverage and systematic post-investment value addition. Over the years, Legend Capital has also become a widely recognized name in bringing together key resources in China and abroad through cross-border business, and a valuable partner for Chinese and foreign investors.

Legend Capital values ​​long-term sustainable investing and integrates ESG into its long-term development strategy. As a UNPRI signatory since November 2019, Legend Capital is among the first group of top venture capital/PE firms in China to join the initiative.

For more information, please visit and follow us on LinkedIn @Legend Capital (


Comments are closed.